Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a downside of -3.25% to close Monday at $1.19 after subtracting -$0.04 on the day. The 5-day average trading volume is 6,674,500 shares of the company’s common stock. It has gained $1.4300 in the past week and touched a new high 1 time within the past 5 days. An average of 7,902,065 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 8,062,080.
TNXP’s 1-month performance is 283.87% or $0.8580 on its low of $0.3151 reached on 12/27/22. The company’s shares have touched a 52-week low of $0.29 and high of $11.52, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, TNXP has achieved 205.28% or $0.8002 and has reached a new high 8 times. However, the current price is down -89.67% from the 52-week high price.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
TNXP stock has a beta of 1.71. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 0.22.
Tonix Pharmaceuticals Holding Corp.’s quick ratio for the period ended June 29 was 11.30, with the current ratio over the same period at 11.30.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 36.06% to -$28.98 million, while revenue of -$27.4 million was 5.45% off the previous quarter. Analysts expected TNXP to announce -$1.44 per share in earnings in its latest quarter, but it posted -$1.22, representing a 15.30% surprise. EBITDA for the quarter stood at more than -$29.34 million. TNXP stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 13.72 million, with total debt at $0.98 million. Shareholders hold equity totaling $57.54 million.
Let’s look briefly at Tonix Pharmaceuticals Holding Corp. (TNXP) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 68.89% to suggest the stock is trending Neutral, with historical volatility in this time period at 212.62%.
The stock’s 5-day moving average is $1.1440, reflecting a -8.46% or -$0.1100 change from its current price. TNXP is currently trading +268.31% above its 20-day SMA, +16.67% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +160.45% and SMA200 by-82.90%.
Stochastic %K and %D was 69.64% and 66.10% and the average true range (ATR) pointed at 0.1819. The RSI (14) points at 70.08%, while the 14-day stochastic is at 67.74% with the period’s ATR at 0.1531. The stock’s 9-day MACD Oscillator is pointing at 0.0678 and 0.2537 on the 14-day charts.
In the most recent analyst report for Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), Noble Capital Markets launched coverage with an Outperform rating. Analysts offering their rating for TNXP stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate TNXP as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is TNXP’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $6.00 and a high of $6.50, with their median price target at $6.50. Looking at these predictions, the average price target given by analysts is for Tonix Pharmaceuticals Holding Corp. (TNXP) stock is $6.33.